尼日利亚HIV-1感染者整合酶抑制剂耐药及衣壳蛋白多样性分析
该研究对尼日利亚87份DTG治疗失败样本深度测序,发现26.0%可基因分型者存在INSTI耐药,G118R为优势通路;33例可评估者中未检出已知LEN原发耐药突变。
要点
- DTG治疗失败者中26.0%检出至少一种INSTI耐药突变,G118R常见。
- 仅12.0%对DTG预测敏感性降低,主要INSTI突变占10%。
- 可评估衣壳序列中未发现已知LEN原发耐药突变。
核心结论
- 成人和儿童DTG治疗失败者中均存在INSTI耐药,G118R为突出耐药通路。
研究设计与样本
- 对尼日利亚87份DTG治疗失败样本深度测序,含成人47例、儿童40例。
- 用Stanford HIVdb和IAS-USA标准判读,低频变异按2%、5%、10%、20%阈值分析。
主要发现
- 50例可整合酶基因分型者中13例(26.0%;95%CI 15.9%-39.6%)对≥1种INSTI耐药。
- 6/50(12.0%;95%CI 5.6%-23.8%)对DTG预测敏感性降低。
- G118R在共识序列中检出4/50,Q148H/K/R和N155H未检出。
- ≥20%阈值下G118R检出8/47;33例完整覆盖6个原发位点者中LEN原发耐药突变0/33(95%CI 0%-10.4%)。
- T107A在可评估的3/33例中检出。
临床怎么用
- DTG治疗失败者应关注G118R等INSTI耐药通路,尤其在西非流行区。
- 推广LEN前需持续监测衣壳蛋白耐药突变。
局限性
- 未评估表型敏感性和临床结局。
- 部分样本衣壳位点覆盖不足,LEN耐药评估受限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dolutegravir (DTG)-based antiretroviral therapy has been widely adopted across sub-Saharan Africa, yet resistance pathways in non-B HIV-1 subtypes remain poorly defined. As lenacapavir (LEN), a long-acting capsid inhibitor, is introduced for prevention and treatment, characterizing baseline capsid variation alongside emerging integrase resistance is increasingly important. Whether DTG resistance pathways coexist with known capsid resistance mutations in West African epidemics remains poorly described. METHODS: We performed deep sequencing of 87 HIV-1 samples from adults (n = 47) and paediatric participants (n = 40) failing DTG-based antiretroviral therapy in Nigeria. Resistance mutations were interpreted using Stanford HIVdb and IAS-USA criteria, with resistance estimates based on gene- or drug-panel-specific denominators. Low-frequency variants were assessed at 2%, 5%, 10% and 20% read-frequency thresholds. Capsid mutations associated with LEN resistance were characterized, structurally mapped and compared to global sequence data. HIV-1 subtype and recombinant forms were assigned using COMET HIV-1 v2.4. RESULTS: At consensus, predicted resistance to ≥1 integrase strand transfer inhibitor (INSTI) was detected in 13/50 integrase-genotypable participants (26.0%; 95% CI 15.9%-39.6%), including 5/50 with a major INSTI resistance mutation. Reduced predicted susceptibility specifically to DTG was present in 6/50 (12.0%; 95% CI 5.6%-23.8%). G118R was detected in 4/50 participants at consensus, while Q148H/K/R and N155H were absent. In exploratory deep-sequencing analysis, G118R was detected in 8/47 participants with sufficient codon-level coverage at the ≥20% read-frequency threshold. No known primary LEN resistance mutation was detected among 33 participants with complete coverage of all six primary resistance positions (0/33; 95% CI 0%-10.4%); T107A, a polymorphic capsid substitution of uncertain effect on LEN susceptibility, was detected in in 3/33 individuals where sequence could be evaluated. CONCLUSIONS: These findings demonstrate DTG resistance in both adult and paediatric participants with virological failure with G118R emerging as a prominent resistance pathway. No known primary LEN resistance mutation was detected in the assessable capsid sequences, although phenotypic susceptibility and clinical outcomes were not evaluated. These findings support continued surveillance of integrase and capsid resistance as long-acting antiretroviral strategies expand.
引用
- Abdullahi A, Osawe S, Wisso H, et al. HIV-1 integrase inhibitor resistance in viraemic-treated individuals and baseline capsid diversity relevant to future lenacapavir therapy. J Antimicrob Chemother. 2026. PMID: 42708709. doi:10.1093/jac/dkag300
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。